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Abstract
Although efficient delivery and distribution of treatment agents over the whole tumor is essential for successful tumor
treatment, the distribution of most of these agents cannot be visualized. However, with single-photon emission
computed tomography (SPECT), both delivery and uptake of radiolabeled peptides can be visualized in a
neuroendocrine tumor model overexpressing somatostatin receptors. A heterogeneous peptide uptake is often
observed in these tumors. We hypothesized that peptide distribution in the tumor is spatially related to tumor
perfusion, vessel density and permeability, as imaged and quantified by DCE-MRI in a neuroendocrine tumor model.
Four subcutaneous CA20948 tumor-bearing Lewis rats were injected with the somatostatin-analog 111In-DTPA-
Octreotide (50 MBq). SPECT-CT and MRI scans were acquired and MRI was spatially registered to SPECT-CT.
DCE-MRI was analyzed using semi-quantitative and quantitative methods. Correlation between SPECT and DCE-
MRI was investigated with 1) Spearman’s rank correlation coefficient; 2) SPECT uptake values grouped into deciles
with corresponding median DCE-MRI parametric values and vice versa; and 3) linear regression analysis for median
parameter values in combined datasets. In all tumors, areas with low peptide uptake correlated with low perfusion/
density/ /permeability for all DCE-MRI-derived parameters. Combining all datasets, highest linear regression was
found between peptide uptake and semi-quantitative parameters (R2>0.7). The average correlation coefficient
between SPECT and DCE-MRI-derived parameters ranged from 0.52-0.56 (p<0.05) for parameters primarily
associated with exchange between blood and extracellular extravascular space. For these parameters a linear
relation with peptide uptake was observed. In conclusion, the ‘exchange-related’ DCE-MRI-derived parameters
seemed to predict peptide uptake better than the ‘contrast amount- related’ parameters. Consequently, fast and
efficient diffusion through the vessel wall into tissue is an important factor for peptide delivery. DCE-MRI helps to
elucidate the relation between vascular characteristics, peptide delivery and treatment efficacy, and may form a basis
to predict targeting efficiency.
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Introduction
The goal of tumor treatment is to efficiently deliver and
distribute the treatment agent over the whole tumor to
maximize treatment efficacy. In certain parts of the tumor,
however, if the treatment agent concentration is too low these
parts may escape treatment. Whereas the distribution of most
treatment agents cannot be imaged, the delivery and uptake of
radiolabeled peptides (which bind to receptors on the tumor cell
membrane) can be visualized using single-photon emission
computed tomography (SPECT). Neuroendocrine tumors
overexpressing somatostatin receptors on the cell membrane
can be imaged with SPECT using radiolabeled somatostatin-
derived peptide analogs that target these receptors [1,2,3,4].
Using these radiolabeled somatostatin-derived peptide-
analogs, neuroendocrine tumors can also be treated by local
irradiation using peptide receptor radionuclide therapy (PRRT)
[5,6,7,8,9]. The current prognosis for patients with pancreatic
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neuroendocrine tumors is poor when the tumor has
metastasized [7,10,11]. In the case of metastatic spread,
surgical treatment is often not possible [7,12] and other
treatment options are limited. Therapy using radiolabeled
somatostatin analogs is an important novel therapeutic option
in patients with irresectable or metastasized pancreatic
neuroendocrine tumors: a benefit of overall survival of several
years has been reported [7,13,14,15]. However, a pre-clinical
study [16] revealed heterogeneous radioactivity distribution in
the tumor in ex vivo autoradiography, even though in vitro
autoradiography demonstrated homogeneous somatostatin-
receptor distribution in vital tumor regions, as illustrated in
Figure 1. This heterogeneous peptide uptake and distribution in
vivo may hamper effective treatment with PRRT.
The heterogeneous peptide distribution may be governed by
physiological factors, including vascular tumor characteristics.
These characteristics can be studied non-invasively with
dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI), which allows to visualize and quantify the
concentration of contrast agent in blood vessels and leakage of
this contrast into tissues. With these images, the extent of
perfusion/density/permeability of the vessels of the tumor can
be examined and spatially correlated to the heterogeneous
uptake of radiolabeled peptide observed with SPECT. This
correlation can provide insight into the influence of tumor
perfusion, vessel density and permeability on peptide
distribution, and may help to improve treatment of
neuroendocrine tumors.
The aim of this study was to assess the spatial correlation of
tumor perfusion, vessel density and permeability with the
uptake and distribution of radiolabeled peptides in a pancreatic
neuroendocrine tumor model (CA20948) in rats.
Material and Methods
Animal and tumor model
For this study male Lewis rats (n=4, Harlan-CPB, Austerlitz,
the Netherlands), weighing ± 300 g were used. All
investigations were carried out in accordance with the
requirements of the institutions concerned and conformed with
the requirements in the Netherlands regarding animal studies.
The protocol was approved by the Ethics Committee for Animal
Research at Erasmus MC, Rotterdam in accordance with
Dutch law (DEC no. EMC 2042).
During imaging the animals were anesthetized with
isoflurane (Nicholas Pyramal Ltd., London, UK), body
temperature was controlled using a heated bed, and all efforts
were made to minimize suffering. Pancreatic tumor cells (106
CA20948 cells) were inoculated subcutaneously in the right
flank. When the tumors reached a diameter of at least 1.5 cm
the animals were imaged. Animals were placed in a dedicated
holder to ensure the same position of the animal and tumor
during both SPECT-CT and MRI imaging. After completion of
the examinations the animals were sacrificed.
Radiolabeling
Radiolabeling of 111In-DTPA-octreotide (OctreoScan,
Covidien, Petten, The Netherlands) was performed by a 30-min
incubation of pentetreoide and 111InCl3. A specific radioactivity
of 7.1 MBq per nmol octreotide (labeling efficiency of >98%)
was used as this could be prepared every day of the week,
Figure 1.  Heterogeneous ex vivo peptide uptake versus homogeneous receptor expression.  Illustration of the
heterogeneous SPECT peptide uptake in ex vivo autoradiography (A), with the corresponding homogeneous receptor expression in
in vitro autoradiography (B), for a pancreatic neuroendocrine tumor model (CA20948).
doi: 10.1371/journal.pone.0077076.g001
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thereby ensuring that all animals received the same amount of
radioactivity and peptide mass.
SPECT-CT imaging
One hour prior to SPECT imaging, all animals received 200
µl 50 ± 2 MBq OctreoScan (1408.5541 g/mol) through the tail
vein under isoflurane anesthesia. SPECT-CT images were
acquired using a 4-head multi-pinhole NanoSPECT/CT camera
(Bioscan, Mediso Medical Imaging Systems, Hungary). The
energy peak settings were 171 and 245 keV (window width ±
10%) for 111In. Nine-pinhole apertures (diameter 2.5 mm) were
used on each camera head, with a transaxial field of view
(FOV) of 60 mm. SPECT images were acquired using 36
projections, 120 s/projection, quality factor 1, and a total scan
time of 36 min. SPECT images were reconstructed using the
OSEM method, with 9 iterations and a voxel size of 0.5x0.5x0.5
mm. CT images were acquired using the following settings: 360
projections, 45kVp tube voltage, 1000 ms exposure time, a
scan time of 9 min, and a voxel size of 0.2x0.2x0.2 mm. In a
post-processing step, the SPECT images were resampled to
the CT resolution. The counts in the SPECT images were
converted to kBq/voxel by the scanner software; these values
were used for the spatial correlation. All data will be made
available upon request.
MRI imaging
Directly after SPECT-CT imaging, MRI images were
acquired. Imaging was performed on a 7.0 Tesla dedicated
animal scanner (Discovery MR901, Agilent Technologies/GE
Healthcare) using a 4-channel surface receiver coil (Rapid MR
International, Ohio, USA). Prior to the DCE-MRI sequence two
additional scans were acquired: 1) high resolution
susceptibility-weighted images (SWI) for registration purposes
using a gradient echo sequence (repetition time (TR) 10 ms;
echo time (TE) 4.5 ms; 6° flip angle; FOV 4 cm; voxel size
0.098x0.098x0.30 mm); and 2) T1-weighted images with
varying TRs for calibration purposes (TR 200, 400, 800, 1200,
2400 ms; TE 8.0 ms; 90° flip angle; FOV 5.0 cm; voxel size
0.207x0.207x0.80 mm).
For accurate DCE-MRI quantification, temporal resolutions <
5 s are advised for animal models to ensure reliable model
fitting and parameter estimation [17]. Therefore, DCE-MRI
images were acquired using time-resolved imaging of contrast
kinetics (TRICKS) to achieve a high temporal resolution: 96
images were made with a temporal resolution of 4.3 s. These
images were acquired in two sequential acquisitions with an
interval of 60 s between the acquisitions, with a total time span
of 8 min. Other acquisition parameters for TRICKS were: TR
3.4 ms, TE 1.0 ms, 10° flip angle, FOV 5.0 cm, and voxel size
0.195x0.195x0.50 mm. The contrast agent (Gadovist, Bayer,
Mijdrecht, The Netherlands) used during MRI scanning was
administered intravenously in the tail vein. A single dosage of
0.2 mmol/kg Gadovist was injected at a constant speed of 1.2
mmol/kg*min. All data will be made available upon request.
Data analysis
Registration MRI with SPECT-CT.  To enable spatial
correlation between MRI and SPECT images, registration
between both modalities is required. SPECT and CT images
were automatically aligned by dedicated software in the
SPECT-CT scanner (InVivo Scope software, Bioscan). For an
unbiased registration between DCE-MRI and SPECT-CT a
separate MRI sequence is required; otherwise, direct use of
DCE-MRI for registration purposes could result in
overestimation of the correlation between DCE-MRI and
SPECT-CT. Therefore, the SWI were acquired for registration
purposes.
The tumors were manually delineated on the SWI and CT
scans and, using these contours, tumor masks were
generated. The SWI masks were registered to the CT masks
using Elastix [18], subsequently applying a rigid and affine
registration scheme. Since use of the dedicated animal holder
ensured that no deformation occurred in tumors between
scanning (MRI/SPECT-CT), non-rigid registration was not
necessary. The transformation parameters acquired from both
registration schemes were then used to transform the DCE-
MRI images to the CT images.
DCE-MRI quantification.  To derive features from the DCE-
MRI data, both a semi-quantitative and a quantitative analysis
method were applied. Semi-quantitative methods can be
computed without acquiring a T1-weighted sequence of scans
for calculating the T10-map, and are therefore better suited for
clinical applications. Analyses were performed using in-house
developed software based on MATLAB (MathWorks, Natick,
MA, USA).
Semi-quantitative analysis.  Signal enhancement over time
curves (SI curves) were constructed for all voxels inside the
tumor mask. Six semi-quantitative parameters were calculated
from the SI curve: 1) maximum enhancement (Smax), 2) time-
to-peak (TTP), 3) area under the whole curve (AUC), 4) area
under the curve for the first 60 s (AUC 60), 5) wash-in, and 6)
wash-out. The wash-in was calculated as the slope between
the 10% point and the 90% point on the enhancement curve,
and the wash-out as the slope of the SI curve between the
point of maximum enhancement and the last time point,
according to Parker et al. [19]. Since the signal intensity in MRI
is relative and can differ between subjects and scanners, semi-
quantitative parameters were normalized to enable comparison
of these parameters between animals. Each parameter was
linearly scaled between the minimum and maximum by using
xnorm=(x -xmin)/(xmax-xmin) resulting in values between 0 and 1.
Quantitative analysis.  The standard compartment model of
Tofts et al. [20] was used to model the pharmacokinetic
behavior of contrast agent inside the tumor. From this model
the following parameters were calculated: Ktrans (s-1), the
capillary transfer constant between the intravascular and the
extravascular extracellular compartments, and kep (s-1), the
contrast exchange rate from the extravascular extracellular
space to the intravascular compartment. Physiologically, Ktrans
is a combination of blood flow and capillary permeability inside
the tumor and its exact physiological interpretation depends on
the balance between this perfusion and permeability [20].
To calculate quantitative DCE-MRI parameters, absolute
MRI values are needed. For this purpose, T1-weighted
sequences with varying repetition times were acquired for the
computation of the T1(0)-map. Using this map, the SI curves
Correlation DCE-MRI with SPECT
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e77076
were converted to contrast-concentration curves. The standard
Tofts compartment model was fitted to the contrast-
concentration curves, resulting in the parametric maps for Ktrans
and kep. For this method an arterial input function (AIF) was
required, which was determined per dataset by fitting a bi-
exponential equation [21] to an average contrast-concentration
curve acquired from the femoral artery.
Correlating DCE-MRI-derived parameters with SPECT
peptide uptake.  For correlation of the DCE-MRI-derived
parameters with SPECT uptake, only voxels within the tumor
boundary were taken into account, excluding the tumor feeding
vessels; all parameters are computed over the same set of
voxels. However, as shown by others [22], the standard
compartment Tofts model sometimes poorly fits for voxels with
low contrast enhancement. In these instances Ktrans and kep
have very high, non-physiological values. For these voxels
(with no or very little contrast agent accumulation in the DCE-
MRI images) Ktrans and kep were set to zero.
The correlation between SPECT and DCE-MRI was
investigated using three different methods. First, Spearman’s
rank correlation coefficients between DCE-MRI-derived
parameters and SPECT-peptide uptake were calculated per
dataset over all tumor voxels. Secondly, for each dataset, the
range of SPECT values was sorted and divided into deciles.
For each subset of voxels within the SPECT decile region, the
same region in the DCE-MRI parameter map was located, and
the median DCE-MRI parameter values for that decile region
were calculated. Similarly, for each dataset the range of DCE-
MRI parameter values was sorted and divided into deciles, and
for each DCE decile region the corresponding median SPECT
values were calculated. Thirdly, median DCE-MRI parameter
values for all 4 datasets were grouped based on the SPECT
deciles and a linear regression analysis was performed.
Results
Figure 2 shows the overlap between SPECT peptide uptake
(in green) and the different DCE-MRI parameters (in red); it can
be seen that low DCE-MRI parameter values coincide with low
SPECT values. However, high DCE-MRI parameter values do
not always result in high SPECT uptake, as can be seen in the
leftmost part of the tumor. Only a few voxels, in the middle of
the dark part, were set to zero due to non-physiological values
in the Ktrans and kep maps. For visualization purposes, the TTP
values were inverted.
The spatial correlation between the SPECT peptide uptake
and the different DCE-MRI parameters was computed using
Spearman’s rank correlation coefficient (ρ) (Table 1). The
average ρ was ≥ 0.52 for all parameters, except for AUC and
Smax. For the individual tumors the highest ρ (0.61-0.63) was
found for wash-in, wash-out, TTP, Ktrans, and kep.
Figure 3 shows the median DCE-MRI parameter values,
together with the Q1 (first quartile) and Q3 (third quartile)
values, per SPECT decile for one tumor. All DCE-MRI
parameters, except for TTP, showed an increase with
increasing SPECT values. Since TTP quantifies elapsed time
until maximum enhancement, TTP decreased with increasing
SPECT deciles. The increase for the AUC and Smax in the
high SPECT deciles was less steep compared with the other
DCE-MRI parameters. The other 3 datasets yielded similar
results (not shown).
Figure 4 shows the inverse relation between SPECT uptake
and the DCE-MRI parameters for one tumor: the median
SPECT values, together with the Q1 and Q3 values, are plotted
as a function of the different DCE-MRI parameter deciles. For
all parameters, except for AUC, AUC60 and Smax, a monotone
increasing or decreasing function was observed. For AUC,
AUC60 and Smax a maximum in the SPECT value is already
reached for lower DCE-MRI parameter values. From that point
on, higher DCE-MRI parameter values correspond to sub-
maximal SPECT values. The other 3 tumors showed similar
relations for all parameters (not shown).
In Figure 5 all datasets are combined. The median value per
parameter as a function of the SPECT decile values is plotted,
together with the highest and lowest median parameter value
of the 4 individual datasets. Linear regression analysis showed
a significant (p < 0.05) correlation between the SPECT uptake
and all DCE-MRI parameters. A high correlation (R2 > 0.7) was
observed for AUC60, TTP, wash-in, and wash-out. For the
other DCE-MRI parameters, the R2 was lower (0.55-0.65) due
to the non-linear relation (AUC, Smax) or to the spread of
median values between the different datasets.
Discussion
This study investigated the influence of tumor perfusion,
vessel density and permeability on the tumor uptake and
distribution of radiolabeled peptides. For this, we evaluated the
spatial correlation between DCE-MRI-derived perfusion
parameters and the radiolabeled peptide distribution in SPECT-
CT for the CA20948 somatostatin receptor-positive pancreatic
tumor model. First, we spatially registered the DCE-MRI
images to the SPECT-CT images, followed by analysis of DCE-
MRI data using a semi-quantitative and a quantitative analysis
method. Voxel-based analysis over the whole tumor showed a
clear relationship between SPECT uptake values and the DCE-
MRI parameters AUC60, TTP, wash-in, wash-out, Ktrans and kep.
Combining all datasets showed a high linear regression
correlation between peptide uptake and AUC60, TTP, wash-in,
and wash-out (R2 > 0.7).
It is established that tumors (even within the same type and
grade) can be very heterogeneous and quantitative imaging
biomarkers are useful to provide important reproducible
estimates of this tumor heterogeneity in vivo [23]. Tumor
heterogeneity is an important factor since it affects treatment
delivery and response. The efficacy of DCE-MRI-derived
parameters for assessing this heterogeneity and its effect on
therapy response is therefore an interesting topic of research
[24,25,26]. However, in such studies anti-tumor response is the
main treatment outcome, and no insight is obtained on the
spatial correlation between the DCE-MRI parameter values and
drug delivery. SPECT enables imaging of the delivery of the
peptide and direct spatial correlation of the distribution of the
peptide to the DCE-MRI parametric maps.
One study reported a visual correlation between gadolinium
enhancement in MRI images and 111In-pentetreotide
Correlation DCE-MRI with SPECT
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(OctreoScan) SPECT images in brain tumors [27]. In a study
by Miyazaki et al. [12], DCE-MRI-derived parameters were
used to monitor changes in patients with neuroendocrine liver
metastases treated using yttrium 90 (90Y)-labeled octreotide
(90Y-DOTATOC) and to predict treatment response. However,
in that study no SPECT images were acquired for a voxel-wise
correlation of the peptide distribution and DCE-MRI parametric
maps. In two recent PET studies, a spatial correlation of
parameters derived from DCE-CT or DCE-MRI with the
distribution of PET tracers was performed to assess tumor
biology [28] and tumor oxygenation status [29]. Metz et al. [28]
reported weak to moderate correlations of PET with DCE-MRI
by thresholding based on tracer uptake, although no significant
correlations were found when the total tumor area was
analyzed. Hansen et al. [29] reported a large variation in
correlation coefficients between subjects. To the best of our
knowledge, no study has compared the distribution and uptake
of radiolabeled peptides with DCE-MRI-derived perfusion
parameters in a neuroendocrine pancreatic tumor model in a
voxel-wise manner.
In the present study, for all parameters it was found that low
parameter values are associated with low peptide uptake. The
highest correlation between DCE-MRI-derived parameters and
peptide uptake was a Spearman’s correlation coefficient of
0.63. The parameters associated with the exchange between
the blood vessels and extracellular extravascular space in the
tumor (such as Ktrans, kep, AUC60, TTP, wash-in and wash-out)
showed higher correlations than the parameters primarily
associated with the total amount of contrast delivered to the
tumor (such as Smax and AUC). Furthermore, for the
‘exchange-related’ parameters a monotonic relation was
observed with the peptide uptake (Figure 4). Regions with high
Figure 2.  Visualization of the correspondence between SPECT-peptide uptake and DCE-MRI-derived parameters.  Color
coded images of SPECT peptide uptake (in Bq) (green) and different DCE-MRI parameters (red) for one slice through the tumor.
Clockwise starting from the top left: AUC, area under the whole curve; AUC60, area under the curve for the first 60 s; Smax,
maximum enhancement; TTP, time to peak; wash-in, slope between the 10% point and the 90% point on the enhancement curve
[19]; wash-out [19]; Ktrans (s-1) capillary transfer constant [20]; kep (s-1), contrast exchange rate [20]. All semi-quantitative parameters
were normalized and TTP values were inverted for visualization purposes.
doi: 10.1371/journal.pone.0077076.g002
Correlation DCE-MRI with SPECT
PLOS ONE | www.plosone.org 5 October 2013 | Volume 8 | Issue 10 | e77076
‘exchange-related’ parameter values showed higher peptide
uptake than regions with low ‘exchange-related’ parameters.
For the parameters associated with the total amount of contrast
delivery, this association showed a distinct optimum: regions
with higher AUC or Smax did not show a higher peptide
uptake. This optimum could be explained by a saturation effect:
a maximum level of peptide accumulation is reached when
somatostatin receptors are saturated, after which further
improvement of delivery will not result in a higher peptide
uptake. As used in these studies, 10 µg of 111In-DTPA-
octreotide will indeed partly saturate the tumor somatostatin
receptors [30,31]. The ‘exchange-related’ parameters seem to
predict peptide uptake better than the ‘contrast amount-related’
parameters. Consequently, fast and efficient diffusion through
the vessel wall and into tissue is an important factor for peptide
delivery. This information could offer a clue for improving
peptide delivery. There are several methods available to
enhance perfusion and/or permeability. For example,
permeability inducing agents or hyperthermia, the latter
enhances both perfusion and permeability [32].
The correlations found in this study are probably an
underestimation, as several factors have limiting effects.
The contrast agent used in the MRI has different
pharmacokinetic properties and thus is not an exact
representation of peptide behavior after leaving the blood
circulation. With DCE-MRI the circulation of contrast agent
during the first 8 min after injection is measured, which
provides information on influx into the tumor, vessel
permeability, and diffusivity of the contrast agent in the tissue.
SPECT is acquired over a period of 30 min, 1 h after
administration of OctreoScan. The SPECT images provide
information on peptide accumulation in tumor cells following
Table 1. Mean and standard deviation (SD) of Spearman’s
correlation coefficient (ρ) between SPECT peptide uptake
and different DCE-MRI parameters, calculated over all
datasets.
DCE-MRI parameter Mean ρ (range) SD
AUC 0.38 (0.27-0.56) 0.13
AUC60 0.52 (0.43-0.56) 0.06
Smax 0.40 (0.25-0.55) 0.12
TTP 0.55 (0.45-0.62) 0.09
wash-in 0.56 (0.47-0.61) 0.06
wash-out 0.55 (0.45-0.61) 0.09
Ktrans 0.55 (0.45-0.61) 0.07
kep 0.55 (0.46-0.63) 0.08
AUC, area under the whole curve
AUC60, area under the curve for the first 60 s
Smax, maximum enhancement
TTP, time to peak wash-in, slope between the 10% point and the 90% point on the
enhancement curve [19]
wash-out, slope between the point of maximum enhancement and the last time
point [19];
Ktrans (s-1), capillary transfer constant [20]
kep (s-1), contrast exchange rate [20]
doi: 10.1371/journal.pone.0077076.t001
circulation through the blood, diffusing through the vessel wall
and into tissue, and subsequent binding and internalization. In
other words, the peptide relies on tumor perfusion and
permeability to reach the targeted cells, but final tumor uptake,
as imaged with SPECT is also determined by peptide-receptor
binding affinity and efficacy, and receptor expression levels.
Therefore, a perfect correlation is not expected. Our data show
that poor perfusion limits the amount of peptide able to reach
the tumor, so that less peptide can bind to the receptor and
internalize into the tumor cells. First and foremost the peptide
needs to be delivered to the tumor; as such, the delivery of
peptides can be adequately studied with a low molecular
weight contrast agent.
Imperfection of registrations between SPECT and MRI could
be another reason for lower correlations between SPECT and
the DCE-MRI parameters. There is an inherent registration
error between SPECT-CT and MRI: since CT and MRI image
different tissue characteristics and have different distortions,
tumor alignment will not be perfect between the modalities,
implying that voxel-wise analysis will not be completely
accurate. An alternative is to use larger voxels. Although this
increases the overlap of voxels that are slightly misregistered,
the use of less voxels also results in loss of information and
homogenization of data.
Underestimation of the correlation can also be due to the
‘blooming effect’ that is inherent to SPECT imaging, together
with the lower SPECT resolution. Regions with low perfusion/
density/permeability, but close to a region with high SPECT
uptake, will distort the correlation. This effect might also explain
the large spread in median values shown in Figures 3 and 4.
Some tumor regions were identified with high DCE-MRI
parameter values but were without peptide uptake as assessed
by SPECT, as can be seen in the leftmost part of the tumor in
Figure 2. Some of these regions were identified (based on
SWI) as well vascularized connective tissue structures
separating different lobes in the tumor; for other regions no
visual clue was present. A homogeneous receptor expression
for neuroendocrine tumors has been reported [16]. In a
previous experiment with the CA20948 pancreatic tumor
model, we also found a homogeneous receptor expression for
vital tumor regions, as illustrated in Figure 1B. This high
parameter value without peptide uptake can be explained by
the dynamic perfusion of the tumor during the time frame of the
different imaging sessions.
In the current study only a small number of animals were
used. Since the aim of this study was to investigate whether
uptake of radiolabeled peptide is correlated to tumor perfusion,
vessel density and permeability, we feel that even with this
limited set of CA 20948 tumors the correlations between
SPECT and DCE-MRI parameters were adequately studied. In
future studies, the effect of the tumor model on the correlation
needs to be investigated.
In summary, for all tumors, areas with low peptide uptake
also showed low values for all DCE-MRI-derived parameters,
which could hamper therapeutic treatment with radiolabeled
peptides in these areas. When all datasets were combined, a
strong linear relation (R2 > 0.7) was found between
radiolabeled peptide uptake imaged with SPECT, and either
Correlation DCE-MRI with SPECT
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AUC60, TTP, wash-in, or wash-out. The average correlation
coefficient between SPECT and DCE-MRI-derived parameters
ranged from 0.52 to 0.56 for AUC60, TTP, wash-in, wash-out,
Ktrans and kep. All these parameters are associated with the
exchange between the blood and extracellular extravascular
space in the tumor. For the parameters primarily associated
with the total amount of contrast delivered to the tumor, such
as Smax and AUC, the average correlation was relatively low
(< 0.4). For these parameters a distinct optimum was observed:
regions with higher Smax or AUC did not show higher peptide
uptake. The ‘exchange-related’ parameters seemed to predict
the peptide uptake better than the ‘contrast amount-related’
parameters. It can be concluded that fast and efficient diffusion
over the vessel wall and into the tissue is an important factor
for peptide delivery.
Conclusion
By correlating radiopeptide uptake in a tumor, quantified by
SPECT imaging, with DCE-MRI-derived parameters, we can
conclude that the vascular characteristics of the tumor play an
important role in the delivery of peptide and thus in targeting
tumor cells. The ‘exchange-related’ parameters AUC60, TTP,
wash-in, wash-out, Ktrans and kep seemed to predict the peptide
uptake better than the ‘contrast amount-related’ parameters
AUC and Smax. Fast and efficient diffusion through the vessel
wall and into tissue is an important factor for peptide delivery.
The application of DCE-MRI-derived parameters in
assessing tumor perfusion, vessel density and permeability
allows to study the effects of vascular characteristics on the
treatment efficacy of PRRT. DCE-MRI can be used to
understand treatment efficacy, and may even serve as a basis
to make predictions on the delivery of radiopeptides in PRRT.
Figure 3.  SPECT decile groups with corresponding median DCE-MRI parameter values.  The median, Q1, and Q3 DCE-MRI
parameter values for the different SPECT decile bins for one tumor. AUC, area under the whole curve; AUC60, area under the
curve for the first 60 s; Smax, maximum enhancement; TTP, time to peak; wash-in, slope between the 10% point and the 90% point
on the enhancement curve [19]; wash-out, slope between the point of maximum enhancement and the last time point [20]; Ktrans (s-1)
capillary transfer constant [20]; kep (s-1), contrast exchange rate [20]. Semi-quantitative parameters were normalized.
doi: 10.1371/journal.pone.0077076.g003
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Figure 4.  DCE-MRI parameter decile groups with corresponding median SPECT-peptide uptake values.  The median, Q1,
and Q3 SPECT values (Bq) for the different DCE-MRI parameter decile bins for one tumor. AUC, area under the whole curve;
AUC60, area under the curve for the first 60 s; Smax, maximum enhancement; TTP, time to peak; wash-in, slope between the 10%
point and the 90% point on the enhancement curve [19]; wash-out, slope between the point of maximum enhancement and the last
time point [19]; Ktrans (s-1) capillary transfer constant [20]; kep (s-1), contrast exchange rate [20].
doi: 10.1371/journal.pone.0077076.g004
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Figure 5.  Linear regression analysis on the grouped datasets.  The median value per parameter for the SPECT decile bins
calculated over all datasets, together with highest and lowest median value per parameter from the 4 individual datasets, and R2
value per parameter from linear regression analysis (p<0.05). AUC, area under the whole curve; AUC60, area under the curve for
the first 60 s; Smax, maximum enhancement; TTP, time to peak; wash-in, slope between the 10% point and the 90% point on the
enhancement curve [19]; wash-out, slope between the point of maximum enhancement and the last time point [19]; Ktrans (s-1)
capillary transfer constant [20]; kep (s-1), contrast exchange rate [20]. Semi-quantitative parameters were normalized.
doi: 10.1371/journal.pone.0077076.g005
Correlation DCE-MRI with SPECT
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